4Sitting HB. Pain reduced and quality of life improved by sustained- release hydromorphone. Results of an observational study [J] . MMW Fortschr Med, 2004, 146 (suppl 3-4) : 95-98.
5Jeanne L, Raymord WH, Robert FK, et al. Cancer pain management with a controlled-release oral morphine preparation [ J] . J Pain Sympt Manag, 1989, 4 (3) : 146-161.
6Shiying YU, Yan SUN, Haichun ZHANG, et al. Transdermal fentanyl for management of cancer pain in elderly patients in China [J] . Chin German J Clin Oneol, 2004, 3 (2) : 85-89.
7Kalso E,Smith L, McQuay HJ,et al. No pain, no gain:clinial ex- cellence anti scientific rigour-lessnns learned from 1A morphine [ J ]. Pain ,2002,98 ( 3 ) :269-275.
8Mitchell P. Engle, Baominh P. Vinh, Nusrat Harun, et al. Infectious Complications Related to Intrathecal Drug Delivery System and Spinal Cord Stimulator System Implantations at a Comprehensive Cancer Pain Center. Pain Physician ,2013, 16:251 - 257.
9Catherine E. Smyth, Virginia Jarvis, Patricia Poulin. Brief review: Neuraxial analgesia in refractory malignant pain. Can J Anesth, 2014,(61):141 - 153.
10Smith TJ, Staats PS, Pool GE, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol, 2002, 20:4040 - 4049.
